Evidence map›Paper›PMID 31264807›Full record

ArticleCancer medicine2019

Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark.

Ingrid Glimelius, Annika Englund, Klaus Rostgaard, Karin E Smedby, Sandra Eloranta, Peter de Nully Brown, Christoffer Johansen, Peter Kamper, Gustaf Ljungman, Lisa Lyngsie Hjalgrim and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Ingrid GlimeliusDepartment of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-6158-3041
Annika EnglundDepartment of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Klaus RostgaardDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Karin E SmedbyDivision of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Sandra ElorantaDivision of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-5806-0573
Peter de Nully BrownDepartment of Haematology, Rigshospitalet, Copenhagen, Denmark.
Christoffer JohansenDanish Cancer Society Research Center, University of Copenhagen, Copenhagen, Denmark.
Peter KamperDepartment of Haematology, Aarhus University Hospital, Aarhus, Denmark.
Gustaf LjungmanDepartment of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Lisa Lyngsie HjalgrimDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Henrik HjalgrimDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Statens Serum Institut · DKUppsala University · SEKarolinska Institutet · SEAarhus University Hospital · DKRigshospitalet · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burden of late effects among Hodgkin lymphoma (HL) survivors treated according to contemporary protocols remains poorly characterized. We used nation-wide registers to assess number of inpatient bed-days and specialist outpatient visits among 1048 HL-patients (<25 years, diagnosed 1990-2010) and 5175 country-, sex-, and age-matched comparators. We followed them for up to 24 years, with time-dependent assessment of relapse status. International Classification of Diseases (ICD-10) chapter-specific hazard ratios (HRs) were assessed in Cox regression analyses, and nonparametric statistics described patterns of health-care-use. Relative to comparators, relapse-free survivors were at increased risk of infections, diseases of the blood, endocrine, circulatory and respiratory systems, and unspecific symptoms, HRs ranging from 1.86 to 3.05. Relative to comparators, relapsed survivors had at statistically significantly increased risk of diseases reflecting practically all investigated disease-chapters, HRs ranging from 1.60 to 18.7. Among relapse-free survivors, 10% of the patients accounted for 80% of all hospital bed days, and 55% were never hospitalized during follow-up. Among relapsed-survivors, 10% of the patients accounted for 50% of the bed days, and only 24% were never hospitalized during follow-up. In contrast, 10% of the comparators accounted for 90% of hospital bed days and 75% were never hospitalized. These findings challenge the impression of a uniformly distributed long-term morbidity among all HL survivors and emphasize the need for early identification and attention to patients particularly susceptible to late effects, such as relapsed survivors.

Indexed as

AdolescentCancer SurvivorsChildChild, PreschoolCohort StudiesDenmarkFemaleFollow-Up StudiesHodgkin DiseaseHospitalizationHumansInfantMaleRecurrenceRegression AnalysisSwedenHodgkin lymphomahospitalizationslate adverse effectsrelapsesurvivorship

Identifiers

PMID31264807
PMCPMC6712477
OpenAlexW2954793033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.